World Health Organization. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA2000; 284: 3043–3045.
2.
University of California San Francisco MS-EPIC Team, CreeBAGourraudPA, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol2016; 80(4): 499–510.
3.
ConwayDSThompsonNRCohenJA.Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes. Mult Scler Relat Disord2016; 9: 129–134.
4.
RioJRoviraATintoreM, et al. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler2018; 24(3): 322–330.
5.
SchulzKFChalmersIHayesRJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995; 273: 408–412.
6.
JadadARMooreRACarrollD, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary. Contr Clin Trials1996; 17(1): 1–12.
7.
BeroLOostvogelFBacchettiP, et al. Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. PLoS Med2007; 4(6): e184.
8.
NoseworthyJHEbersGCVandervoortMK, et al. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology1994; 44: 16–20.
9.
MoherDSchulzKFAltmanDG, et al. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med2001; 134: 657–662.
